The study is the first large-scale clinical trial to show that a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer.
As 2025 comes to a close, economists, analysts and other experts begin to look ahead to the new year and what we can expect in 2026. With the economy faltering and the Trump administration’s attempts to exert unprecedented influence on institutions of ...